University of California

Other

Pfizer Corporation

The Scripps Research Institute

Biogen Ma Inc.

Biogen Idec Ma Inc.

Shangpharma Innovation Inc.

Shanghai Chempartner Co., Ltd

Dean Sheppard

Robert Pytela

Amha Atakilit

William F Degrado

Hyunil Jo

Xiaozhu Huang

Aparna Sundaram

Paul H Weinreb

Kenneth J Simon

Shelia Marie Violette

Neil Cowan Henderson

Diane R Leone

Isaac J Rondon

Joel McIntosh

Vito Quaranta

Richard Thomas Beresis

Joseph Dal Porto

Dharmaraj Samuel

Dominique Meyer

Nilgun Isik Reed

Charles Ray Holst

Youzhi Tang

Matthew Ross Drever

Kyle Steven Niessen

Marc Adler

George Wen Su

Rosemary J Akhurst

Kamran Atabai

Sayyed M Amin Khalifeh-Soltani

Rosemary J Akurst

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to αvβ8 integrin. The invention includes uses, and associated methods of using the antibodies.

Method of treating cancer using anti-AV8 antibodies

Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.

Inhibitors of alpha 2 beta 1 integrin and methods of use thereof

Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.

Inhibitors of integrin alpha 2 beta 1 and methods of use

The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

Alpha-5 beta-1 inhibitors

Methods and compositions comprising integrin &#x3b2;8 antibodies are provided.

Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to &#x3b1;v&#x3b2;8 integrin. The invention includes uses, and associated methods of using the antibodies.

Anti-AVB8 antibodies and compositions and uses thereof

Disclosed herein, inter alia, are inhibitors of integrin alpha 5 beta 1 and methods of using the same.

Inhibitors of integrin alpha 5 beta 1 and methods of use

Provided herein, inter alia, are methods and compositions for inhibiting &#x3b1;v&#x3b2;1 integrin and for treating fibrosis.

Anti-alphavbeta1 integrin inhibitors and methods of use

Anti-alphavbeta1 integrin compounds and methods

The present invention provides compositions and methods for treating and preventing disease associated with &#x3b1;v&#x3b2;5 integrin by blocking binding to &#x3b1;v&#x3b2;5 integrin. In particular, antibodies specific for &#x3b1;v&#x3b2;5 integrin are useful for preventing, treating, and reversing sepsis.

Methods and compositions for treating and preventing disease associated with &#x3b1;v&#x3b2;5 integrin

Methods and compositions for regulating fatty acid uptake and/or decreasing gastric motility in an animal are provided. The method comprises administering an antagonist of integrin &#x3b1;&#x3b2;or &#x3b1;&#x3b2;to an animal in an amount sufficient to reduce fatty acid uptake in the animal, thereby reducing fatty acid uptake in the animal. In some embodiments, the antagonist is an antibody. Also provided is a method of increasing fatty acid uptake and/or gastric motility in an animal.

Milk fat globule epidermal growth factor 8 regulates fatty acid uptake

Antibodies (e.g., isolated antibodies) that specifically bind to human integrin &#x3b2;8 and inhibit adhesion of latency associated peptide (LAP) to &#x3b1;v&#x3b2;8 are provided. In some embodiments, the antibody cross-reacts with mouse integrin &#x3b2;8. In some embodiments, the antibody blocks TGFJ3 activation. In some embodiments, the antibody antagonizes binding of LAP to &#x3b1;&#x3b2;8 with an IC50 below 5 nM.

Methods and compositions for treating and preventing disease associated with alpha-V beta-8 integrin

Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.

[object Object]

Monoclonal antibodies that specifically bind to &#x25a1;v&#x25a1;&#x25a1;. Also included are methods of using these antibodies to treat mammals having or at risk of having &#x25a1;v&#x25a1;6-mediated diseases, or to diagnose &#x25a1;V&#x25a1;6-mediated diseases.

Growing community of inventors

Oakland, CA, United States of America

Dean Sheppard